Newsroom | 19420 results

BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, une société de biotechnologie spécialisée dans la médecine régénérative qui développe des thérapies cellulaires de nouvelle génération, a annoncé aujourd’hui qu’elle présenterait de nouvelles données précliniques sur le TFG-001 lors de la 7e Conférence mondiale sur la maladie de Parkinson. Le TFG-001, une thérapie cellulaire à base de microtissus neuronaux 3D, a démontré une libération rapide de dopamine et une réinnervation étendue déri...

BORDEAUX, Frankreich--(BUSINESS WIRE)--TreeFrog Therapeutics, ein Biotech-Unternehmen im Bereich der regenerativen Medizin, das Zelltherapien der nächsten Generation entwickelt, gab heute bekannt, dass es auf der 7. Welt-Parkinson-Konferenz neue präklinische Daten zu TFG-001 vorstellen wird. TFG-001, eine 3D-neural-mikrogewebezelltherapie, zeigte in mehreren fortgeschrittenen translationalen Parkinson-Modellen eine schnelle Dopaminfreisetzung und eine umfassende, vom Transplantat ausgehende Rei...

BORDEAUX, Frankrijk--(BUSINESS WIRE)--TreeFrog Therapeutics, een biotech-bedrijf gericht op regeneratieve geneeskunde dat celtherapieën van de nieuwe generatie ontwikkelt, maakte vandaag bekend dat het bedrijf nieuwe preklinische gegevens over TFG-001 zal voorstellen tijdens de 7e World Parkinson’s Conference. TFG-001, een 3D neurale microweefsel-celtherapie, bewees snelle afgifte van dopamine en uitgebreide herbezenuwing afkomstig van transplantaten bij verschillende translationele modellen va...

BORDEAUX, Francia--(BUSINESS WIRE)--TreeFrog Therapeutics, biotech specializzata nella medicina rigenerativa e nello sviluppo di terapie cellulari di prossima generazione, oggi ha annunciato che presenterà nuovi dati preclinici su TFG-001 alla 7a conferenza mondiale sulla malattia di Parkinson. TFG-001 è una terapia cellulare basata su microtessuti neurali 3D che ha dimostrato un rilascio rapido di dopamina e un'estesa reinnervazione a seguito di graft in diversi modelli traslazionali della mal...

BURDEOS, Francia--(BUSINESS WIRE)--TreeFrog Therapeutics, una empresa biotecnológica dedicada a la medicina regenerativa que desarrolla terapias celulares de última generación, ha anunciado hoy que presentará nuevos datos preclínicos sobre el TFG-001 en la 7.ª World Parkinson's Conference. TFG-001, una terapia celular basada en microtejidos neuronales 3D, ha demostrado una rápida liberación de dopamina y una reinervación extensa derivada del injerto en múltiples modelos traslacionales avanzados...

BORDEAUX, France--(BUSINESS WIRE)--TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. Th...

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, today announced that new real-world evidence evaluating whole-genome sequencing-based homologous recombination deficiency phenotyping has been accepted for online publication at the 2026 American Society of Clinical Oncology Annual Meeting. The abstract, titled “Whole-genome HRD phenotyping as a predictor of PARP...

TOKYO--(BUSINESS WIRE)--Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive genomic profiling tests at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Chicago. Data from 14 abstracts will be presented on copy number loss detection, serial circulating tumor DNA (ctDNA) genomic profiling, Foundation Medicine’s proprietary...